<bill session="112" type="h" number="4384" updated="2019-11-15T21:18:13Z">
  <state datetime="2012-04-18">REFERRED</state>
  <status>
    <introduced datetime="2012-04-18"/>
  </status>
  <introduced datetime="2012-04-18"/>
  <titles>
    <title type="short" as="introduced">Patient Safety and Drug Labeling Improvement Act</title>
    <title type="display">Patient Safety and Drug Labeling Improvement Act</title>
    <title type="official" as="introduced">To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.</title>
  </titles>
  <sponsor bioguide_id="V000128"/>
  <cosponsors>
    <cosponsor bioguide_id="B001259" joined="2012-04-18"/>
  </cosponsors>
  <actions>
    <action datetime="2012-04-18">
      <text>Introduced in House</text>
    </action>
    <action datetime="2012-04-18" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2012-04-20">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="112" type="s" number="2295" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Consumer affairs"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Health information and medical records"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2012-05-15T17:21:37Z" status="Introduced in House">Patient Safety and Drug Labeling Improvement Act - Amends the Federal Food, Drug, and Cosmetic Act to allow the holder of an approved abbreviated new drug application (generic drug approval) to change the labeling of a drug so approved in the same manner authorized by regulation for the holder of an approved new drug application.

Allows conforming changes to be ordered to the labeling of the equivalent listed drug and each drug approved under the abbreviated new drug application process that corresponds to such listed drug.</summary>
</bill>
